Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis.

"Declarations Ethics approval and consent to participateThe study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Research Ethics Committee of “Hospital de la Santa Creu I Sant Pau” (IIBSP-IIL-2020–148; 1 March 2021). Informed consent was obtained from all patients involved in the study.Consent for publication.Not applicable. Competing interestsHC has received grants for research and attendance at conferences from Grünenthal, MSD, BIogen, Galapagos, Roche, BMS and honorarium for advisory boards from Galapagos, Gebro, Abbvie, Sanofi, UCB. Competing interests HC has received grants for research and attendance at conferences from Grünenthal, MSD, BIogen, Galapagos, Roche, BMS and honorarium for advisory boards from Galapagos, Gebro, Abbvie, Sanofi, UCB."

"Funding This research was supported in part by a 2020–2021 grant by “Societat Catalana de Reumatologia”. This work was supported by the Instituto de Salud Carlos III (JR20/00008 for Pau Riera)."